UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Latecomer experimental drug no better than Dupixent in trial
by Kim Yun-mi
2019-06-24 15:49
Off-label use of Mabthera Inj. denied
by Kim Yun-mi
2019-06-20 15:49
‘Korean cancer researchers have risen to world-class level’
by Kim Yun-mi
2019-06-20 15:04
‘Immunotherapies contributed to advancement of neoadjuvant cancer treatment’
by Kim Yun-mi
2019-06-19 15:36
AstraZeneca to invest $630 million in Korean biohealth sector
by Kim Yun-mi
2019-06-17 11:33
라인
‘Moon administration to expand investment into healthcare, quality of life’
by Kim Yun-mi
2019-06-14 16:49
Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug
by Kim Yun-mi
2019-06-12 13:29
Forxiga prevents kidney disease in diabetes patients
by Kim Yun-mi
2019-06-11 15:40
HIV prevention pill to get insurance benefit in Korea
by Kim Yun-mi
2019-05-30 13:25
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
by Kim Yun-mi
2019-05-29 12:35
라인
‘Enstilum treats all psoriasis from mild to severe ones’
by Kim Yun-mi
2019-05-28 14:44
‘Risk-sharing agreements back up economic feasibility review’
by Kim Yun-mi
2019-05-22 14:46
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too?
by Kim Yun-mi
2019-05-21 14:19
Low-income, single women more vulnerable to osteoporosis
by Kim Yun-mi
2019-05-20 15:40
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride
by Kim Yun-mi
2019-05-15 15:30
라인
Keytruda wins nod as adjuvant therapy after melanoma surgery
by Kim Yun-mi
2019-05-15 14:14
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon
by Kim Yun-mi
2019-05-13 14:23
Xeljianz is easier to use than biologic therapies -- is it safer, however?
by Kim Yun-mi
2019-05-10 15:34
[Exclusive] MSD Korea playing tricks to reduce daycare cost
by Kim Yun-mi
2019-05-09 11:20
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too
by Kim Yun-mi
2019-05-07 14:30
-
이전
11
12
13
14
15
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top